Email PDF
Image-1Email PDF


Avelumab for injection

Solution for Intravenous Infusion

  • 20 mg/mL

Professed Standard Therapeutic Classification: Antineoplastic

BAVENCIO has been issued marketing authorization with conditions, pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for BAVENCIO please refer to Health Canada’s Notice of Compliance with conditions - drug products web site.

BAVENCIO is indicated for the treatment of:

  • Metastatic Merkel cell carcinoma (MCC) in previously treated adults.
  • Patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.
Action SVG
Action SVG
Action SVG